Hummingbird Bioscience, a Singapore-based innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, closed an extended Series B funding round of US$25m.
The round, which brings the total capital raised through financing activities and strategic partnerships to more than US$65m to date, was led by new investor SK Holdings, with participation from existing shareholders including Heritas Capital and SEEDS Capital, the investment arm of Enterprise Singapore.
The company will use the new funds to accelerate development of new candidates into clinical trials and strengthen its scientific and research and development capabilities.
Led by Dr Piers Ingram, Chief Executive Officer and co-founder, Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics.
The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.
It is located in Singapore, Houston, Texas and South San Francisco, California.